Background
Brian Rifkin
Potassium Rollercoaster Heartbreak

This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.

Potassium Rollercoaster Heartbreak
Background
Jade Teakell
FLOZINATing to the Future- Long Term Effects of ...

This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?

FLOZINATing to the Future- Long Term Effects of Empagliflozin in Patients with CKD
Background
Brian Rifkin
The Ondansetron Ballet: Torsades de Pointes

Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?

The Ondansetron Ballet: Torsades de Pointes
Background
Cristina Adriana Popa
Re”FINE”ing the role of non steroidal MRAs in ...

This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?

Re”FINE”ing the role of non steroidal MRAs in Cardio Kidney Metabolic syndrome
Background
Cristina Adriana Popa
Playing It Safe: Can Felzartamab Fill the Gap ...

This week is time antibody mediated rejection treatment in kidney transplant. A new molecule targeting CD38, on the horizon, safely tested in a phase 2 trial

Playing It Safe: Can Felzartamab Fill the Gap in AMR Treatment?

Tonight's NephJC Tweetchat is all about aPLA2R

aPLA2R is the first blood test specifically for nephrotic syndrome. It has recently been licensed by the FDA and we want to have an open and frank discussion on how this test may be used in clinical medicine. To aid in this discussion we will be looking at two papers.

The first was highlighted by CJASN's eJC and was covered summarized by Joel Topf and his Fellow, Bilal Saleem:

The second article was published this past Spring in NDT. It is an industry sponsored trial of ACTH for the treatment of membranous nephropathy. Swapnil Hiremath summarized it for #NephJC

And additionally here is a link to the KDIGO Glomerulonephritis Recommendations.

Please join us on Twitter at 9pm Eastern Daylight. Use the hashtag #NephJC.

NephJC made the FOAM Reduction e-mail mailing list

FOAM Reduction bills itself as a Twitter-free means of receiving FOAM (free open access medical education). The July 25th edition touched on the recent hyponatremia guidelines and included a shout out to our TweetChat. We are honored.

“Hyponatremia

Rumor has it that hyponatremia is near the top of UpToDate’s most searched list. Probably because it is so damn common (15-20% of hospital admissions) and the algorithm is a pain. Enter the Hyponatremia Guideline Development Group (I want to party with these guys), who recently published a new clinical practice guideline for diagnosis and treatment of hyponatremia. It is surprisingly easy to follow, by eliminating volume status guesses and depending on urine osmolality, urine sodium to determine the etiology of water excess.

The guideline can be found here and if you want a more expert take on the guidelines, a group of nephrologists performed a Twitter-based journal club (#NephJC, @nephjc) dissection on the guideline here.

I included the diagnosis algorithm from the new guideline below, along with the algorithm I see used most often.”


Our newsletter just went out and it is a doozy

Did we mention we had a news letter? (please sign up)

If you were on the mailing list, you can see the letter here. The e-mail covers three important pieces of NephJC news

1

Our next TweetChat is next Tuesday at 9 PM. We are looking at the NEJM article about VUR prophylaxis. Interesting paper. Pascal Lane did a wonderful summary of the study.

2

We are changing the way we do video interviews. These will no longer be scheduled events but, instead will get done when we can arrange a time with the most interesting scientists willing to talk to us.

3

We are exploring the possibility of doing a Live NephJC during Kidney Week in Philadelphia. We have a four question Survey Monkey to try to gauge how much interest there is in this idea.

NephJC.com user statistics

I have been a dedicated Mac user since 1991 and the turn around that Apple has pulled off never ceases to amaze me. Look at the OS distribution of readers of NephJC.com. Apple has 59% of visitors between iPhone and MacOSX. Incredible.

But I don't think all of the credit can be given to Stevie J and his merry band of Nexters. Look at the twin debacles of Vista and Win8. Together, those two OS's can't smell the OS share of XP whose latest update was over 6 years ago!

Just got a great e-mail from a lurker

Just after we finished the Mesoamerican Nephropathy twitter chat I received the following e-mail:

What a great comment. We usually measure success by the number of people that engage in the conversation but there is another group of people who listen without talking. Great to hear from one of them to remind us that there are multiple ways to get value from NephJC.

Big props to Nature Reviews Nephrology for opening up their #NephJC article

The editors of Nature Reviews Nephrology were some of NephJC's earliest supporters. One of the ways they supported us was by suggesting an article for discussion. We decided to use that article and they even made that article open access. This is a limited time offer so make sure you run over to their site and download the study. We are so appreciative of all the support the crew at Nature Reviews Nephrology has offered NephJC. Thank-you guys.

We will be discussing this interesting Perspective on Twitter at 9PM Eastern on Tuesday July 8. Use hashtag #NephJC.

Google Hangout in 90 minutes!

NephJC will be doing a live Google Hangout tonight, Tuesday at 9pm EDT. We will have Somjot Brar, the lead author of POSEIDON and Peter McCullough cardiologist and expert on contrast nephropathy joining Joel Topf.

We will try to take questions from people watching, so tweet your questions with the hashtag #NephJC and we will forward them on to our panel of experts.

At the end of the discussion we will announce the next NephJC article.



We have a winner to the coffee challenge!

Last week in the e-mail announcement for the TweetChat we had a trivia contest. We asked what has more sugar, a lightly sweetened cup of coffee or all of the plasma in all of the body of an euglycemic adult?

Almost immediatly we got the following tweet:

Which is correct! Eoin will be enjoying his lightly sweetened coffee from a new NephJC coffee mug just as soon as the boat delivers it across the pond. Congratulations Eoin!

Screen Shot 2014-07-01 at 9.16.43 AM.png